Use of significant point methodology to prevent inappropriate therapy

• US 8,521,276 B2
• Filed: 01/11/2011
• Issued: 08/27/2013
• Est. Priority Date: 01/12/2010
• Status: Expired due to Fees

• Current Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Original Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Inventors: Sweeney, Robert J., Li, Dan
• Primary Examiner(s): Sweet, Thomas J
• Assistant Examiner(s): Shah, Krutanjali M
• Application Number:
  US13/004,582
• Publication Number:
  US 20110172729A1
• Time in Patent Office: 959 Days
• Field of Search: 607/4, 607/5, 607/7, 607/14, 600/510, 600/509, 600/516, 600/517, 600/518, 600/521
• US Class Current: 607/5
• CPC Class Codes: A61B 5/363 Detecting tachycardia or bradycardia
• CPC Class Codes: A61N 1/36507 controlled by gradient or slope of the heart potential
• CPC Class Codes: A61N 1/3925 Monitoring; Protecting

Abstract

An apparatus example comprises a cardiac signal sensing circuit configured to provide a sensed cardiac signal representative of cardiac depolarization events of a subject, a sampling circuit coupled to the cardiac signal sensing circuit, a therapy circuit, and a controller communicatively coupled to the sampling circuit and the therapy circuit. The controller includes a detection module configured to detect tachyarrhythmia using the cardiac signal and a signal analysis module configured to establish significant points (SPs) of the sampled cardiac signal, estimate heart rate during the tachyarrhythmia using the SPs, and provide an indication of whether noise is present in the cardiac signal using the SPs. The controller is configured to select a therapy for delivery by the therapy circuit in response to the tachyarrhythmia detection and to modify the selected therapy according to the heart rate estimation and the noise indication.

Claims

1. An apparatus comprising:

a cardiac signal sensing circuit configured to provide a sensed electrical cardiac signal representative of cardiac activity of a subject;

a sampling circuit coupled to the cardiac signal sensing circuit;

a therapy circuit, configured to provide one or more of high-energy cardioversion shock therapy, high-energy defibrillation shock therapy, and anti-tachycardia pacing (ATP) to the heart; and

a controller communicatively coupled to the sampling circuit and the therapy circuit, wherein the controller includes;

a detection module configured to detect tachyarrhythmia using the cardiac signal; and

a signal analysis module configured to;

establish significant points (SPs) of the sampled cardiac signal, wherein an SP corresponds to a time of occurrence of a turn encountered in the cardiac signal;

perform autocorrelation of the SPs in an SP domain;

perform a second autocorrelation of the SP autocorrelation;

calculate a number of SPs per heart beat from an SP shift that produces a peak in the second autocorrelation; and

estimate heart rate during the tachyarrhythmia using the number of SPs per heart beat; and

determine a likelihood of the presence of noise in the cardiac signal using the SPs,

and wherein the controller is configured to select a therapy for delivery by the therapy circuit in response to the tachyarrhythmia detection and to modify the selected therapy according to the heart rate estimation and the determined likelihood of noise.

2. The apparatus of claim 1, wherein the signal analysis module is configured to determine a probability of noise in the cardiac signal using the SPs.

3. The apparatus of claim 2, wherein the signal analysis module is configured to:

identify a number of approximate SP pairs in the cardiac signal, wherein an approximate SP pair includes two SPs that satisfy a specified matching criterion;

calculate the probability of noise in the cardiac signal using the number of approximate SP pairs; and

determine the likelihood of noise according to the calculated noise probability.

4. The apparatus of claim 2, wherein the signal analysis module is configured to:

determine a number of SPs per second in the cardiac signal;

calculate the probability of noise in the cardiac signal using the number of SPs per second; and

determine the likelihood of noise according to the calculated noise probability.

5. The apparatus of claim 1, wherein the signal analysis module is configured to:

filter the SP autocorrelation; and

calculate a number of SPs per heart beat from an SP shift that produces a peak in the filtered autocorrelation.

6. The apparatus of claim 1, wherein the controller is configured to change a selected therapy type to a less aggressive therapy type when the estimated heart rate is within a lowest tachyarrhythmia detection rate zone and a noise assessment indicates that a probability of noise is above a noise probability threshold value.

7. The apparatus of claim 1, wherein the controller is configured to withhold delivery of the selected therapy when a noise assessment indicates that a probability of noise is above a noise probability threshold value and the estimated heart rate is lower than a lowest tachyarrhythmia detection rate zone.

8. The apparatus of claim 1,

wherein the detection module is configured to detect tachyarrhythmia when heart rate determined from heart beats sensed in the cardiac signal exceeds a tachyarrhythmia detection rate threshold or interval threshold;

and

wherein the controller is configured to withhold delivery of the selected therapy when a noise assessment indicates that a probability of noise is above a noise probability threshold value and the heart rate estimated using the SPs differs by more than a specified threshold value from the heart rate determined from the sensed cardiac signal.

9. The apparatus of claim 1,

wherein the detection module is configured to detect tachyarrhythmia when heart rate determined from heart beats sensed in the cardiac signal exceeds a tachyarrhythmia detection rate threshold or interval threshold;

and

wherein the controller is configured to deliver a type of therapy less aggressive than the selected therapy when a noise assessment indicates that a probability of noise is above a noise probability threshold value, and the heart rate estimated using the SPs is within or below a lowest tachyarrhythmia detection rate zone.

10. A method comprising:

sampling a sensed cardiac signal using a medical device that delivers at least one of high-energy cardioversion, high-energy defibrillation shock therapy, and anti-tachycardia pacing (ATP), wherein the sensed cardiac signal is an electrical signal representative of cardiac activity of a subject;

detecting tachyarrhythmia using the cardiac signal; and

, in response to the tachyarrhythmia detection;

selecting a therapy for delivery by the medical device;

establishing significant points (SPs) of the sampled cardiac signal, wherein an SP corresponds to a turn encountered in the cardiac signal;

estimating heart rate during the tachyarrhythmia using the SPs, wherein estimating heart rate using the SPs includes;

performing autocorrelation in an SP domain;

performing a second autocorrelation of the SP autocorrelation; and

calculating a number of SPs per heart beat from an SP shift that produces a peak in the second autocorrelation;

determining a likelihood of a presence of noise in the cardiac signal using the SPs; and

modifying the selected therapy according to the rate estimation and the determined likelihood of noise.

11. The method of claim 10, wherein determining a likelihood of a presence of noise includes determining a probability of noise in the cardiac signal using the SPs.

12. The method of claim 11, wherein determining a probability of noise includes identifying a number of approximate SP pairs in the cardiac signal and calculating the probability of noise in the cardiac signal using the number of approximate SP pairs, wherein an approximate SP pair includes two SPs that satisfy a specified matching criterion.

13. The method of claim 11, wherein determining a probability of noise includes calculating the probability of noise in the cardiac signal using a number of SPs per second in the cardiac signal.

14. The method of claim 10, wherein estimating heart rate using the SPs includes:

performing autocorrelation in an SP domain;

filtering the SP autocorrelation; and

calculating a number of SPs per heart beat from an SP shift that produces a peak in the filtered autocorrelation.

15. The method of claim 11, wherein modifying the selected therapy includes changing a selected therapy type to a less aggressive therapy type when the estimated heart rate is within a lowest tachyarrhythmia detection rate zone and the probability of noise is above a noise probability threshold value.

16. The method of claim 11, wherein modifying the selected therapy includes withholding delivery of the selected therapy when the probability of noise is above a noise probability threshold value and the estimated heart rate is lower than a lowest tachyarrhythmia detection rate zone.

17. The method of claim 11,

wherein detecting tachyarrhythmia using the cardiac signal includes detecting tachyarrhythmia when heart rate determined from the cardiac signal exceeds a tachyarrhythmia detection rate threshold or interval threshold;

and

wherein modifying the selected therapy includes withholding delivery of the selected therapy when the probability of noise is above a noise probability threshold value and the heart rate estimated using the SPs differs by more than a specified threshold value from the heart rate determined from the sensed cardiac signal.

18. The method of claim 11,

wherein detecting tachyarrhythmia using the cardiac signal includes detecting tachyarrhythmia when heart rate determined from the cardiac signal exceeds a tachyarrhythmia detection rate threshold or interval threshold;

and

wherein modifying the selected therapy includes withholding delivery of the selected therapy when the probability of noise is above a noise probability threshold value, the heart rate estimated using the SPs differs by less than a specified threshold value from the heart rate determined from the sensed cardiac signal, and the heart rate estimated using the SPs is less than a lowest tachyarrhythmia detection rate zone.